ReP USP - Resultado da busca

Artigo de periodico
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial (2019)
Ray, Kausik K; Colhoun, Helen M; Szarek, Michael; Baccara-dinet, Marie; Bhatt, Deepak L; Bittner, Vera A; Budaj, Andrzej J; Diaz, Rafael; Goodman, Shaun G; Nicolau, José Carlos
Source: Lancet diabetes & endocrinology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DIABETES MELLITUS, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAY, Kausik K et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, v. 7, n. 8, p. 618-628, 2019Tradução . . Disponível em: https://doi.org/10.1016/S2213-8587(19)30158-5. Acesso em: 16 nov. 2024.
APA
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-dinet, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, 7( 8), 618-628. doi:10.1016/S2213-8587(19)30158-5
NLM
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
Vancouver
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
Artigo de periodico
Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial (2019)
Steg, Philippe Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Bregeault, Marie-France; Dalby, Anthony J; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Nicolau, José Carlos
Source: Circulation. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, Philippe Gabriel et al. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, v. 140, n. 2, p. 103-112, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.118.038840. Acesso em: 16 nov. 2024.
APA
Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Bregeault, M. -F., Dalby, A. J., et al. (2019). Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 140( 2), 103-112. doi:10.1161/CIRCULATIONAHA.118.038840
NLM
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Vancouver
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Artigo de periodico
Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial (2019)
Szarek, Michael; White, Harvey D; Schwartz, Gregory G; Alings, Marco; Bhatt, Deepak L; Bittner, Vera A; Chiang, Chern-En; Diaz, Rafael; Edelberg, Jay M; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, SÍNDROME CORONARIANA AGUDA, ESTATINAS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SZAREK, Michael et al. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, v. 73, n. 4, p. 387-396, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.10.039. Acesso em: 16 nov. 2024.
APA
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, 73( 4), 387-396. doi:10.1016/j.jacc.2018.10.039
NLM
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039
Vancouver
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 16 nov. 2024.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system (2018)
Bahia, Luciana R.; Santos, Raul D.; Araujo, Denizar V.; Rosa, Roger S.; Bahia, Luciana R.
Source: Archives of endocrinology metabolism. Unidade: FM
Subjects: PACIENTES INTERNADOS, CUSTOS DOS CUIDADOS DE SAÚDE, DOENÇAS CARDIOVASCULARES, HIPERCOLESTEROLEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BAHIA, Luciana R. et al. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, v. 62, n. 3, p. 303-308, 2018Tradução . . Disponível em: https://doi.org/10.20945/2359-3997000000030. Acesso em: 16 nov. 2024.
APA
Bahia, L. R., Santos, R. D., Araujo, D. V., Rosa, R. S., & Bahia, L. R. (2018). Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, 62( 3), 303-308. doi:10.20945/2359-3997000000030
NLM
Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 nov. 16 ] Available from: https://doi.org/10.20945/2359-3997000000030
Vancouver
Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 nov. 16 ] Available from: https://doi.org/10.20945/2359-3997000000030
Artigo de periodico
Clinical Genetic Testing for Familial Hypercholesterolemia (2018)
Sturm, Amy C.; Santos, Raul D.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, DOENÇAS CARDIOVASCULARES, COLESTEROL, CUSTOS DOS CUIDADOS DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STURM, Amy C. e SANTOS, Raul D. Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 72, n. 6, p. 662-680, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.05.044. Acesso em: 16 nov. 2024.
APA
Sturm, A. C., & Santos, R. D. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, 72( 6), 662-680. doi:10.1016/j.jacc.2018.05.044
NLM
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Vancouver
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 16 nov. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) (2018)
Danchin, Nicolas; Santos, Raul D.
Source: European journal of preventive cardiology. Unidade: FM
Subjects: ESTATINAS, DOENÇAS CARDIOVASCULARES, COLESTEROL, LIPOPROTEÍNAS LDL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DANCHIN, Nicolas e SANTOS, Raul D. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, v. 25, n. 10, p. 1087-1094, 2018Tradução . . Disponível em: https://doi.org/10.1177/2047487318777079. Acesso em: 16 nov. 2024.
APA
Danchin, N., & Santos, R. D. (2018). Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, 25( 10), 1087-1094. doi:10.1177/2047487318777079
NLM
Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/2047487318777079
Vancouver
Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/2047487318777079
Artigo de periodico
Familial hypercholesterolaemia (2017)
Defesche, Joep C.; Gidding, Samuel S.; Harada-Shiba, Mariko; Santos Filho, Raul Dias dos; Wierzbicki, Anthony S.
Source: Nature reviews disease primers. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DEFESCHE, Joep C. et al. Familial hypercholesterolaemia. Nature reviews disease primers, v. 3, 2017Tradução . . Disponível em: https://doi.org/10.1038/nrdp.2017.93. Acesso em: 16 nov. 2024.
APA
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Santos Filho, R. D. dos, & Wierzbicki, A. S. (2017). Familial hypercholesterolaemia. Nature reviews disease primers, 3. doi:10.1038/nrdp.2017.93
NLM
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Vancouver
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Artigo de periodico
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD (2017)
Charytan, David M.; Burdmann, Emmanuel de Almeida
Source: American journal of kidney diseases. Unidade: FM
Subjects: FALÊNCIA RENAL CRÔNICA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M. e BURDMANN, Emmanuel de Almeida. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, v. 70, n. 4, p. 522-531, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/21785. Acesso em: 16 nov. 2024.
APA
Charytan, D. M., & Burdmann, E. de A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, 70( 4), 522-531. doi:10.1053/j.ajkd.2017.04.018
NLM
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 16 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Vancouver
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 16 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785

USP Schools

ReP

Filtros

Authors

Subjects

Source title

Funding Agencies